GlassScriptPhysician profile
Naim Alkhouri
NPI 1134336662
$1,922,211.09
in general payments reported to CMS, 2019-2025
62 companies · $607K in 2025
The $607K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $231K · 2020: $69K · 2021: $84K · 2022: $249K · 2023: $309K · 2024: $374K · 2025: $607K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $629K · Consulting Fee: $502K · Travel and Lodging: $106K · Food and Beverage: $24K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $21K · Honoraria: $5,600 · Education: $8.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $629,009.22 |
| Consulting Fee | $502,453.63 |
| Travel and Lodging | $106,337.01 |
| Food and Beverage | $24,456.47 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,390.00 |
| Honoraria | $5,600.00 |
| Education | $8.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $336,630.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Perspectum Diagnostics LTD | $270,744.50 | 2022-2024 | Livermultiscan |
| Ipsen Biopharmaceuticals, INC | $169,633.09 | 2023-2025 | Iqirvo, Bylvay |
| Novo Nordisk INC | $163,161.43 | 2021-2025 | Wegovy |
| Gilead Sciences, INC. | $155,568.13 | 2019-2025 | Livdelzi, Epclusa |
| Intercept Pharmaceuticals, INC. | $124,886.12 | 2019-2024 | Ocaliva |
| Boehringer Ingelheim International Gmbh | $104,673.26 | 2021-2025 | |
| Abbvie INC. | $98,093.60 | 2019-2025 | Mavyret |
| Alexion Pharmaceuticals, INC. | $85,961.58 | 2019-2025 | Kanuma |
| Shionogi INC | $80,619.60 | 2019-2020 | |
| Eisai INC. | $48,407.31 | 2019-2023 | |
| Novo Nordisk As | $44,093.57 | 2022-2025 | |
| Echosens North America, INC. | $42,047.09 | 2020-2024 | Fibroscan |
| Merck Sharp & Dohme LLC | $31,251.42 | 2020-2025 | |
| Sonic Incytes Medical Corp. | $25,000.00 | 2025 | Velacur |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16,851.79 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15,852.36 | 2022-2025 | |
| Siemens Medical Solutions USA, INC. | $14,154.46 | 2022-2023 | |
| Exelixis INC. | $13,957.49 | 2019 | |
| Albireo Pharma, INC. | $13,361.76 | 2023 | Bylvay |
| Dova Pharmaceuticals | $12,491.83 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12,352.84 | 2019-2025 | Xifaxan, Plenvu |
| Mirum Pharmaceuticals, INC. | $9,126.01 | 2023-2025 | Livmarli |
| Theratechnologies INC. | $8,552.87 | 2020-2022 | |
| Regeneron Pharmaceuticals, INC. | $7,061.56 | 2024-2025 | |
| Glaxosmithkline, LLC. | $4,031.63 | 2024-2025 | |
| Ipsen Bioscience INC. | $3,320.00 | 2025 | |
| W. L. Gore & Associates, INC. | $2,392.86 | 2022-2023 | Gore Cardioform Septal Occluder |
| Ucb Sa | $2,080.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,841.23 | 2022-2025 | Entyvio |
| Vbi Vaccine (Delaware) INC. | $1,810.00 | 2022 | |
| Cook Medical LLC | $519.95 | 2022-2023 | Echotip |
| Allergan, INC. | $211.16 | 2019 | |
| Boston Scientific Corporation | $201.45 | 2021-2022 | |
| Janssen Biotech, INC. | $157.41 | 2023-2025 | Tremfya, Stelara, Simponi |
| Sysmex America, INC. | $141.67 | 2023 | Caresphere Workflow Solution |
| Amicus Therapeutics, INC. | $140.00 | 2019 | |
| Lilly USA, LLC | $125.00 | 2023 | |
| Sirtex Medical INC | $107.31 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $100.00 | 2024 | Utaswako Afp-L3 |
| Orphalan INC | $79.84 | 2023-2024 | Cuvrior |
| Travere Therapeutics, INC. | $74.58 | 2019-2023 | Cholbam |
| Histosonics, INC. | $59.16 | 2024 | |
| Intra-Sana Laboratories | $45.53 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $33.42 | 2019 | |
| Evoke Pharma, INC. | $30.91 | 2023-2025 | Gimoti |
| Amgen INC. | $30.01 | 2023-2025 | Uplizna, Amjevita |
| Qol Medical, LLC | $24.67 | 2025 | Sucraid |
| Grifols USA, LLC | $22.22 | 2020 | |
| La Jolla Pharmaceutical Company | $22.02 | 2019 | |
| Alnylam Pharmaceuticals INC. | $20.17 | 2021 | |
| Braintree Laboratories, INC. | $19.72 | 2024 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $18.82 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.84 | 2025 | Voquezna |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,985.30 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naim Alkhouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.